Treatment Outcomes for Patients With t(11;14) Translocation Multiple Myeloma
Posted: Tuesday, August 6, 2019
For patients with t(11;14) translocation multiple myeloma, findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract 8015) indicate that proteasome inhibitors plus immunomodulatory drugs may result in the best survival outcomes. Additionally, concluded Brian G. Durie, MD, of Cedars-Sinai Medical Center, Los Angeles, and colleagues, patients with t(11;14) who underwent early treatment of stem cell transplants also recorded improved survival outcomes.
In this multicenter study—designed and conducted by the International Myeloma Working Group—the investigators used a retrospective cohort of 848 patients who were diagnosed with multiple myeloma with t(11;14) translocation between 2005 and 2015. This translocation was identified on fluorescent in situ hybridization within 6 months of diagnosis.
After a median follow-up of 45.7 months, 84.7% of the patients were alive. When assessed for International Staging System distribution, 35.3% of patients had stage 1 multiple myeloma, 38.9% had stage II disease, and 25.8% had stage III. The investigators found that upon initial treatment, 24.3% of the patients were treated with immunomodulatory drugs, 41.0% received proteasome inhibitors, 20.8% received both immunomodulatory drugs and proteasome inhibitors, and 13.8% did not receive any novel treatment.
An early stem cell transplant procedure was employed in 40.8% of the patients. After the initial treatment, the median time until subsequent treatment was 15 months. For the entire cohort, the median overall survival after diagnosis was 82.5 months.
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.
